BN Business News
Add your company to Business Communicator →

Finance & markets · 18/11/20261 min read

mAbxience and OncoPrecision Announce Manufacturing and Investment Agreement for OncoPrecision's ADC Candidate ONC001

EDITORIAL ILLUSTRATIONF&Finance & marketsBN
Illustration generated by Business News; it is not a source photograph.

Summary

MADRID, Nov. 18, 2026 — mAbxience, a wholly owned company of Fresenius SE & Co. KGaA, and OncoPrecision, a biotechnology company pioneering first-in-class precision therapies for hard-to-treat cancers through the integration of patient-derived biology and AI, headquartered...

Original source language: PR Newswire UK — News ReleasesOpen original release →

Explore insights

Business insights →